Precigen (NASDAQ:PGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Precigen (NASDAQ:PGEN) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02, Zacks reports. The business had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.30 million. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%.

Precigen Trading Up 0.6 %

Precigen stock traded up $0.01 during midday trading on Thursday, reaching $1.80. The company’s stock had a trading volume of 1,290,966 shares, compared to its average volume of 1,174,767. The stock has a market cap of $527.16 million, a PE ratio of -3.27 and a beta of 1.58. Precigen has a 52 week low of $0.65 and a 52 week high of $2.17. The business has a 50-day moving average price of $1.58 and a 200-day moving average price of $1.14.

Analysts Set New Price Targets

A number of research firms recently commented on PGEN. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Precigen in a research note on Thursday. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.